Skip to main content
Top
Published in: Virology Journal 1/2013

Open Access 01-12-2013 | Research

The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China

Authors: Fengming Yi, Jie Zhao, Rishi Vishal Luckheeram, Yuan Lei, Changgao Wang, Sha Huang, Lu Song, Wei Wang, Bing Xia

Published in: Virology Journal | Issue 1/2013

Login to get access

Abstract

Background

The etiology of inflammatory bowel disease (IBD) is not clear and cytomegalovirus (CMV) infection is often associated with IBD patients. The etiologic link between IBD and CMV infection needs to be studied. The objective of the present study is to investigate the prevalence and risk factors of CMV in a cohort of IBD patients from Central China.

Methods

Two hundred and twenty six IBD patients (189 ulcerative colitis (UC) and 37 patients with Crohn’s disease (CD)), and 290 age and sex matched healthy controls were recruited. CMV DNA was detected by nested PCR, while serum anti-CMV IgG and anti-CMV IgM was determined by ELISAs. Colonoscopy/enteroscopy with biopsy of diseased tissues and subsequent H&E stain were then conducted in IBD patients with positive anti-CMV IgM. Finally, we analyzed the prevalence and clinical risk factors of CMV infection in IBD patients.

Results

The prevalence of CMV DNA and anti-CMV IgG positive rate in IBD patients were 84.07% and 76.11%, respectively, higher than those in healthy controls (59.66% and 50.69%, respectively, P < 0.05), However, anti-CMV IgM positive rate was no different with healthy controls (1.77% vs 0.34%, P = 0.235). In univariate analysis of risk factors, the recent use of corticosteroid was associated with increase of CMV DNA and IgM positive rate in UC (P = 0.035 and P = 0.015, respectively), aminosalicylic acid drug therapy was correlated with positivity of CMV DNA and IgG in UC and CMV DNA in CD (P = 0.041, P < 0.001 and P = 0.014, respectively), the treatment of immunosuppresent was correlated with CMV IgM (P < 0.001). Furthermore, patients with severe UC were significantly associated with CMV DNA and IgM (P = 0.048 and P = 0.031, respectively). Malnutrition (albumin < 35 G/L) was also found to be related with CMV recent infection (P = 0.031). In multivariate analysis of risk factors in UC, pancolitis was significantly associated with CMV DNA positivity (P = 0.001). Severe UC and pancolitis seemed to be related with IgG positivity. For CD, there was just single factor associated with CMV positive in each group, multivariate analysis was unnecessary.

Conclusions

CMV positive rate in IBD patients was significantly higher, than in healthy controls. The use of aminosalicylic acid, corticosteroid, immunosuppressants, pancolitis and severe IBD patients seemed to be more susceptible to CMV infection in univariate analysis of risk factors. However, no risk factor was found to be significantly correlated with CMV infection in multivariate analysis of risk factors.
Literature
1.
go back to reference Jiang L, Xia B, Li J, Ye M, Yan W, Deng C, Ding Y, Luo H, Hou W, Zhao Q, Liu N, Ren H, Hou X, Xu H: Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006, 12: 212-217. 10.1097/01.MIB.0000201098.26450.aePubMedCrossRef Jiang L, Xia B, Li J, Ye M, Yan W, Deng C, Ding Y, Luo H, Hou W, Zhao Q, Liu N, Ren H, Hou X, Xu H: Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006, 12: 212-217. 10.1097/01.MIB.0000201098.26450.aePubMedCrossRef
2.
go back to reference Maher MM, Nassar MI: Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig Dis Sci 2009, 54: 2456-2462. 10.1007/s10620-008-0639-6PubMedCrossRef Maher MM, Nassar MI: Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig Dis Sci 2009, 54: 2456-2462. 10.1007/s10620-008-0639-6PubMedCrossRef
3.
go back to reference Kandiel A, Lashner B: Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006, 101: 857-2865.CrossRef Kandiel A, Lashner B: Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006, 101: 857-2865.CrossRef
4.
go back to reference Kim JJ, Simpson N, Klipfel N, Debose R, Barr N, Laine L: Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci 2010, 55: 1059-1065. 10.1007/s10620-010-1126-4PubMedCrossRef Kim JJ, Simpson N, Klipfel N, Debose R, Barr N, Laine L: Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci 2010, 55: 1059-1065. 10.1007/s10620-010-1126-4PubMedCrossRef
5.
go back to reference Lévêque N, Brixi-Benmansour H, Reig T, Renois F, Talmud D, Brodard V, Coste JF, De Champs C, Andréoletti L, Diebold MD: Low frequency of cytomegalovirus infection during exacerbations of inflammatory bowel diseases. J Med Virol 2010, 82: 1694-1700. 10.1002/jmv.21877PubMedCrossRef Lévêque N, Brixi-Benmansour H, Reig T, Renois F, Talmud D, Brodard V, Coste JF, De Champs C, Andréoletti L, Diebold MD: Low frequency of cytomegalovirus infection during exacerbations of inflammatory bowel diseases. J Med Virol 2010, 82: 1694-1700. 10.1002/jmv.21877PubMedCrossRef
6.
go back to reference de Saussure P, Lavergne-Slove A, Mazeron MC, Alain S, Matuchansky C, Bouhnik Y: A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20: 1323-1327. 10.1111/j.1365-2036.2004.02273.xPubMedCrossRef de Saussure P, Lavergne-Slove A, Mazeron MC, Alain S, Matuchansky C, Bouhnik Y: A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20: 1323-1327. 10.1111/j.1365-2036.2004.02273.xPubMedCrossRef
7.
go back to reference D’Ovidio V, Vernia P, Gentile G, Capobianchi A, Marcheggiano A, Viscido A: Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFα therapy. J Clin Virol 2008, 43: 180-183. 10.1016/j.jcv.2008.06.002PubMedCrossRef D’Ovidio V, Vernia P, Gentile G, Capobianchi A, Marcheggiano A, Viscido A: Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFα therapy. J Clin Virol 2008, 43: 180-183. 10.1016/j.jcv.2008.06.002PubMedCrossRef
8.
go back to reference Roback JD, Hillyer CD, Drew WL, Laycock ME, Luka J, Mocarski ES, Slobedman B, Smith JW, Soderberg-Naucler C, Todd DS, Woxenius S, Busch MP: Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors. Transfusion 2001, 41: 1249-1257. 10.1046/j.1537-2995.2001.41101249.xPubMedCrossRef Roback JD, Hillyer CD, Drew WL, Laycock ME, Luka J, Mocarski ES, Slobedman B, Smith JW, Soderberg-Naucler C, Todd DS, Woxenius S, Busch MP: Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors. Transfusion 2001, 41: 1249-1257. 10.1046/j.1537-2995.2001.41101249.xPubMedCrossRef
9.
go back to reference Revello MG, Gerna G: Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 2002, 15: 680-715. 10.1128/CMR.15.4.680-715.2002PubMedPubMedCentralCrossRef Revello MG, Gerna G: Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 2002, 15: 680-715. 10.1128/CMR.15.4.680-715.2002PubMedPubMedCentralCrossRef
10.
go back to reference Chinese Medical Association: Chinese consensus on standard management of inflammatory bowel diseases. Zhonghua Xiao Hua Za Zhi 2007, 27: 545-550. Chinese Medical Association: Chinese consensus on standard management of inflammatory bowel diseases. Zhonghua Xiao Hua Za Zhi 2007, 27: 545-550.
11.
12.
go back to reference Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn’s disease activity index.National cooperative Crohn’s disease study. Gastroenterology 1976, 70: 439-444.PubMed Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn’s disease activity index.National cooperative Crohn’s disease study. Gastroenterology 1976, 70: 439-444.PubMed
13.
go back to reference Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA: Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001, 96: 2137-2142. 10.1111/j.1572-0241.2001.03949.xPubMedCrossRef Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA: Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001, 96: 2137-2142. 10.1111/j.1572-0241.2001.03949.xPubMedCrossRef
14.
go back to reference Boeckh M, Boivin G: Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998, 11: 533-554.PubMedPubMedCentral Boeckh M, Boivin G: Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998, 11: 533-554.PubMedPubMedCentral
15.
go back to reference Numata S, Nakamura Y, Imamura Y, Honda J, Momosaki S, Kojiro M: Rapid quantitative analysis of human cytomegalovirus DNA by the real-time polymerase chain reaction method. Arch Pathol Lab Med 2005, 129: 200-204.PubMed Numata S, Nakamura Y, Imamura Y, Honda J, Momosaki S, Kojiro M: Rapid quantitative analysis of human cytomegalovirus DNA by the real-time polymerase chain reaction method. Arch Pathol Lab Med 2005, 129: 200-204.PubMed
16.
go back to reference Hinnant KL, Rotterdam HZ, Bell ET, Tapper ML: Cytomegalovirus infection of the alimentary tract: a clinicopathological correlation. Am J Gastroenterol 1986, 81: 944-950.PubMed Hinnant KL, Rotterdam HZ, Bell ET, Tapper ML: Cytomegalovirus infection of the alimentary tract: a clinicopathological correlation. Am J Gastroenterol 1986, 81: 944-950.PubMed
17.
go back to reference Kishore J, Ghoshal U, Ghoshal UC, Krishnani N, Kumar S, Singh M, Ayyagari A: Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol 2004, 53: 1155-1160. 10.1099/jmm.0.45629-0PubMedCrossRef Kishore J, Ghoshal U, Ghoshal UC, Krishnani N, Kumar S, Singh M, Ayyagari A: Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol 2004, 53: 1155-1160. 10.1099/jmm.0.45629-0PubMedCrossRef
18.
go back to reference Pofelski J, Morand P, Roblin X, Gratacap B, Nicod S, Bargues G, Seigneurin JM, Bonaz B: Caractérisation moléculaire du cytomégalovirus dans le maladies inflammatoires cryptogénetiques de l’intestin. Gastroenterol Clin Biol 2005, 29: A9. Pofelski J, Morand P, Roblin X, Gratacap B, Nicod S, Bargues G, Seigneurin JM, Bonaz B: Caractérisation moléculaire du cytomégalovirus dans le maladies inflammatoires cryptogénetiques de l’intestin. Gastroenterol Clin Biol 2005, 29: A9.
19.
go back to reference Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A: Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis 2006, 12: 879-884. 10.1097/01.mib.0000231576.11678.57PubMedCrossRef Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A: Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis 2006, 12: 879-884. 10.1097/01.mib.0000231576.11678.57PubMedCrossRef
20.
go back to reference Yee YK, Wong SW, Szeto ML: Ulcerative colitis exacerbation associated with cytomegalovirus infection. Hong Kong Med J 1998, 4: 437-439.PubMed Yee YK, Wong SW, Szeto ML: Ulcerative colitis exacerbation associated with cytomegalovirus infection. Hong Kong Med J 1998, 4: 437-439.PubMed
21.
go back to reference Pfau P, Kochman ML, Furth EE, Lichtenstein GR: Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient. Am J Gastroenterol 2001, 96: 895-899. 10.1111/j.1572-0241.2001.03672.xPubMedCrossRef Pfau P, Kochman ML, Furth EE, Lichtenstein GR: Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient. Am J Gastroenterol 2001, 96: 895-899. 10.1111/j.1572-0241.2001.03672.xPubMedCrossRef
22.
go back to reference Onyeagocha C, Hossain MS, Kumar A, Jones RM, Roback J, Gewirtz AT: Latent cytomegalovirus infection exacerbates experimental colitis. Am J Pathol 2009, 175: 2034-2042. 10.2353/ajpath.2009.090471PubMedPubMedCentralCrossRef Onyeagocha C, Hossain MS, Kumar A, Jones RM, Roback J, Gewirtz AT: Latent cytomegalovirus infection exacerbates experimental colitis. Am J Pathol 2009, 175: 2034-2042. 10.2353/ajpath.2009.090471PubMedPubMedCentralCrossRef
23.
go back to reference Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, Bland KI, Cobbs CS: Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 2002, 360: 1557-1563. 10.1016/S0140-6736(02)11524-8PubMedCrossRef Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, Bland KI, Cobbs CS: Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 2002, 360: 1557-1563. 10.1016/S0140-6736(02)11524-8PubMedCrossRef
24.
go back to reference Eddleston M, Peacock S, Juniper M, Warrell DA: Severe cytomegalovirus infection in inmmunocompetent patients. Clin Infect Dis 1997, 24: 52-56. 10.1093/clinids/24.1.52PubMedCrossRef Eddleston M, Peacock S, Juniper M, Warrell DA: Severe cytomegalovirus infection in inmmunocompetent patients. Clin Infect Dis 1997, 24: 52-56. 10.1093/clinids/24.1.52PubMedCrossRef
Metadata
Title
The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China
Authors
Fengming Yi
Jie Zhao
Rishi Vishal Luckheeram
Yuan Lei
Changgao Wang
Sha Huang
Lu Song
Wei Wang
Bing Xia
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2013
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-10-43

Other articles of this Issue 1/2013

Virology Journal 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine